Fundamentals Are Strong, page-55

It might be a $1.5B company now (1.5b shares at $1), prior to the Teva acquistion 12 months ago it was a $1.1B company, 880m shares x say $1.40 (prior to the surge to $2 on the back of the acquisition)

And a minor point to consider, the MCS division earns money from providing services, they where about 10% of gross profit at half year, and there should be different expectations on services compared to production.

Looking forward, average forecast return on equity for FY17 from analysts is about 8.75 (from ft.com), which doesnt seem surprising to me, according to Morningstar quantitative research (via nabtrade), the sector median is 12.5, country median is 11.4.

So ROE would have to improve 42% to get to the sector median, i expect there are economies of scale from growing the portfolio that are yet to be realised, e.g. Greenville expansion. And also new products yet to come online, but they have to be weighed against declining revenue from old products as competitors products come online also, im really not sure what sort of net revenue growth we should expect.